Martin Dietrich, MD, PhD

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.